Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
726 Leser
Artikel bewerten:
(2)

Agfa-Gevaert Group enters into exclusive negotiations for the sale of a part of its HealthCare IT activities to Dedalus Holding S.p.A. - Regulated information

?

Mortsel, Belgium - December 2, 2019 - 8.30 a.m. CET

As announced on May 14, 2019, the Board of Directors decided to investigate the sale of a part of Agfa HealthCare in the framework of the Agfa-Gevaert Group's transformation process.

Today, the Agfa-Gevaert Group announces that it has entered into exclusive negotiations with Dedalus Holding S.p.A. to sell a part of its HealthCare IT business (the "Business"). The Business consists of the Healthcare Information Solutions and Integrated Care activities, as well as the Imaging IT activities to the extent that these activities are tightly integrated into the Healthcare Information Solutions activities. This is the case mainly in the DACH region, France and Brazil.

The proposed transaction is subject to customary employees' consultations, regulatory approvals and closing conditions. It is expected that, upon positive conclusion of the negotiations, the transaction will be completed in the course
of Q2 2020.

As a result of this transaction, Dedalus Holding S.p.A. would acquire 100% of the Business at an enterprise value of 975 million Euro, subject to regular working capital and net debt adjustments.

Christian Reinaudo, CEO of the Agfa-Gevaert Group, said: "The expected sale of the Business, which generates around 260 million Euro of full year revenues, will represent another milestone in our transformation process. We are looking forward to this important step. We believe that under Dedalus Holding S.p.A.'s ownership, the Business will continue to develop into a leading pan-European player in the HealthCare IT market.
Going forward, Agfa HealthCare will focus on Imaging IT Solutions, continuing on its strategic track to deliver superior value to its customers, led by its flagship Enterprise Imaging platform. It is our ambition to grow revenues and raise the EBITDA margin performance over time from today's mid-single digit percentage of revenues to a double digit level."

This announcement contains inside information.


About Agfa
The Agfa-Gevaert Group develops, manufactures and distributes an extensive range of analogue and digital imaging systems and IT solutions, mainly for the printing industry and the healthcare sector, as well as for specific industrial applications.

Agfa's headquarters and parent company are located in Mortsel, Belgium.

The Agfa-Gevaert Group achieved a turnover of 2,247 million euro in 2018.

Contact:

Viviane Dictus

Director Corporate Communications

tel. ++32 0 3 444 7124

e-mail: viviane.dictus@agfa.com

About Dedalus

Founded in 1990 in Florence, Dedalus, with over 2.000 employees, of which 1.200 in Italy, 550 in France and teams in 25 countries, is an international industrial group in the healthcare software industry specialized in the segment of diagnostic and clinical management solutions (HCIS), GPs and Primary care management, Interoperability and Population health management.

In 2016, the European Private Equity Fund Ardian acquired the 60% of the Dedalus Group boosting its international expansion and strengthening the R&D activities, which is now composed by more than 600 people.

Today, Dedalus exploits the full functional coverage of all ICT needs of any healthcare system, not limited to hospital systems, both public and private. In the last three years, Dedalus has totally renewed its offering, by addressing the state of art of paradigm in terms of technology and functionalities to anticipate the evolution of the clinical practice at the base of the change management of different healthcare system that in many countries are rethinking their organizations.

With more than 130 million euros of revenues in Italy, more than 60 million euros in France and globally more than 210 million euros, Dedalus is one of the leading global players in the sector and holds a leading position in Europe.

Attachment

  • CO_20191202_UK (https://ml-eu.globenewswire.com/Resource/Download/8694a319-0001-4eb6-9a42-c9f018796cb7)
© 2019 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.